ApalyRx
For Manufacturers

Your DTE Channel. Ready to Activate.

ApalyRx provides the operational, regulatory, and technology infrastructure for manufacturer direct-to-employer programs. Your product, your pricing, your commercial strategy. ApalyRx is the platform that makes it executable at scale.

Schedule a Briefing
500K+
Covered lives
92
NPS
20%+
Cost reduction
2018
Operating since
HIPAASOC 2Patent Pending 2026
The Strategic Decision

Does Your Organization Have a Direct-to-Employer Model?

The employer-sponsored health plan market represents one of the most significant untapped opportunities in pharmaceutical distribution. Self-funded employers bear the direct cost of their members' drug spend and are actively seeking manufacturer-direct access that removes intermediary margin and replaces opacity with accountability.

A direct-to-employer channel is not a concept that can be tested with a single employer before committing resources. Every deployment uses the same core infrastructure: 3PL fulfillment, DSCSA documentation systems, pharmacy credentialing across 50 states, demand forecasting, and plan contracting. That infrastructure must be operational before the first script is processed.

ApalyRx has built and operates that infrastructure. The question is not whether to construct it. It is whether your organization chooses to access what is already operational, or to watch other manufacturers establish the direct-to-employer standard first.

The Operational Model

One New Ship-To Address.
ApalyRx Handles Everything Else.

What the Channel Requires
3PL Fulfillment Relationship
ApalyRx contracts and manages the 3PL. The manufacturer ships to one designated address on the existing monthly bulk cadence, identical to any distributor shipment. No 3PL negotiation, contract management, or operational oversight required.
Per-Script DSCSA T3 Documentation
The manufacturer provides bulk serialization data per current procedures. The ApalyRx patent-pending Distribution Engine generates and retains all per-script T3 documentation automatically. No manufacturer system builds required.
Employer-Direct Pricing and MFN Compliance
WAC is preserved across all channels. A per-drug program rebate defined in the supply agreement is applied as a line deduction on the monthly invoice. One invoice, one rebate line, one payment. No new pricing tier, no MFN exposure.
Pharmacy Credentialing Across 50 States
ApalyRx LLC maintains written delegation agreements with all participating pharmacies of record. ApalyRx manages credentialing nationally. No pharmacy relationships to establish or manage.
Cold Chain and Fulfillment Logistics
ApalyRx manages all fulfillment from the 3PL ship-to address forward: temperature controls, last-mile delivery, and pharmacy pickup routing. Physical risk during custody and transit is covered by cargo insurance maintained in the ApalyRx-3PL agreement.
Direct Employer Contracts
Channel conflict is eliminated by structure, not by contract language. ApalyRx is the single counterparty, and existing PBM relationships remain intact.
ERISA and Plan Sponsor Compliance
ApalyRx manages all health plan contracting, fee disclosure, and Consolidated Appropriations Act compliance obligations. The manufacturer's only plan-related document is the master supply agreement with ApalyRx.
Member-Level Sell-Through Data
Monthly dispense, adherence, prescriber attribution, and program performance reports delivered through the platform reporting portal. This is data the standard distributor channel structurally cannot provide: sell-through, not sell-in.
Platform Architecture

Three Engines. One Integrated System.

Built on a patent-pending architecture that handles every function from prescription intake to supplier payment. No existing distribution model, specialty pharmacy, or compliance tool has combined these capabilities in a single platform.

01

Prescription and Member Engagement Engine

Receives electronic prescriptions from any intake pathway. Verifies member eligibility in real time. Interacts with members electronically for pharmacy selection and cost-share collection. Executes prescription transfer. Settles all parties simultaneously at dispense.

02

Multi-Channel Lowest Net Cost Routing Engine

Evaluates every in-scope prescription across all plan-activated supply channels in real time, including manufacturer-direct and other available options. Routes to the most appropriate channel based on plan rules, program eligibility, and net cost. Every routing decision is documented at the decision level.

03

Distribution and DSCSA Compliance Engine

Manages the serialized virtual pre-allocation pool for manufacturer-direct custodial inventory. Generates DSCSA-compliant per-prescription T3 documentation at the individual dispense level without a change-of-ownership trigger at the 3PL. Administers just-in-time replenishment against the enrolled member census.

Commercial Structure

Transparent, Auditable Economics

WAC Preserved

Across all channels

One Counterparty

One invoice. One payment.

< 30 Days

Inventory dwell time at 3PL

Pricing mechanism

The manufacturer invoices at WAC. A per-drug employer-direct program rebate, defined in the master supply agreement, is applied as a line deduction on the monthly invoice. Net payment is WAC minus the rebate. This structure preserves most-favored-nation integrity because manufacturer rebates are almost universally excluded from MFN calculations under existing contracts.

Data exchange

ApalyRx provides monthly member-level utilization reporting, adherence metrics, prescriber attribution, and program performance data through the platform. This is sell-through visibility at the member level, actual dispense events, that the traditional wholesale distribution channel does not provide to manufacturers by default.

Common Questions

Answers for Every Internal Stakeholder

Does this require new logistics or warehouse infrastructure?

No. The manufacturer's one operational change is shipping to an ApalyRx-designated 3PL facility rather than a distributor warehouse. ApalyRx owns and manages the 3PL relationship entirely. All documentation and downstream fulfillment are handled by ApalyRx.

Do we need new DSCSA systems?

No. The manufacturer provides serialization data per current procedures. The ApalyRx platform handles all per-script T3 documentation as a technology service. No manufacturer system builds required.

Who manages cold chain during transit?

The manufacturer ships to the ApalyRx-designated 3PL using existing cold chain protocols. ApalyRx bears responsibility for cold chain management from the 3PL forward. Cold chain standards are contractual obligations in the ApalyRx-3PL service agreement.

How does revenue recognition work?

Revenue is recognized at point of title transfer, occurring upon physical receipt at the member's preferred local pharmacy. This is a discrete, documentable event recorded by the ApalyRx platform. The monthly invoice reflects all title transfer events in the prior month.

What is our credit exposure?

The manufacturer's counterparty is ApalyRx. Credit exposure is evaluated against ApalyRx as the contracting entity. The manufacturer has no direct financial relationship with any health plan.

How does this interact with gross-to-net?

In the standard distribution chain, gross-to-net erosion compounds at every intermediary. Wholesaler fees, chargeback administration, PBM rebate holds of 90 to 180 days, and specialty pharmacy spread all reduce the manufacturer's realized net price in ways that are difficult to model in advance and reconcile after the fact. In the ApalyRx channel, WAC is preserved as the transaction price. The per-drug program rebate is defined in the supply agreement and applied at dispense, not held and reconciled quarters later. There are no chargebacks, no distributor fees, and no spread. GTN for every unit is calculable at the point of dispense: WAC minus the contracted rebate, period. The result is a channel where the manufacturer knows the realized net price before the script is filled, not six months after.

Does this create new wholesale distribution obligations?

No. The 3PL is a licensed third-party logistics provider, not a wholesale distributor. Custody transfer to the 3PL without title transfer does not trigger wholesale distribution requirements under DSCSA or state law.

Does the manufacturer contract with health plans?

No. The manufacturer's only counterparty is ApalyRx. Employer demand is transmitted by proxy through ApalyRx as the authorized channel operator. The manufacturer has no direct employer relationships to establish or defend.

Will this trigger MFN provisions?

The WAC with employer-direct program rebate structure is designed to avoid triggering MFN provisions. WAC is preserved across all channels. Manufacturer legal teams should validate the specific MFN language in their PBM contracts against this structure.

Is this a pilot program?

No. This is a live channel infrastructure built and operated by ApalyRx. 3PL fulfillment, DSCSA documentation systems, pharmacy credentialing across 50 states, and plan contracting are all operational today.

How does this affect existing PBM relationships?

The program is designed to function alongside existing PBM benefits. Health plans direct specific high-cost specialty drugs through the program while maintaining their PBM for the broader formulary. The manufacturer's existing formulary arrangements for all other drugs are unchanged.

What does the manufacturer gain that no other channel provides?

Complete control over gross-to-net, with WAC preserved and rebates applied at dispense rather than held 90 to 180 days by intermediaries. Real-time member-level sell-through data, prescriber attribution, adherence metrics, and a locked formulary position within employer-configured drug programs. No other channel gives the manufacturer pricing control, data visibility, and formulary commitment simultaneously.

Implementation

Operational in Six Months

Phase 1Months 1–2

Agreement and Commercial Framework

  • Master supply agreement
  • Technology services agreement for DSCSA engine
  • Per-drug rebate schedule structured and documented
Phase 2Months 2–3

Platform Integration

  • DSCSA engine integration with manufacturer serialization data
  • JIT forecast calibration to first employer census
  • 3PL product setup and serialized inventory ingestion
Phase 3Month 4

Inaugural Employer Launch

  • First live deployment
  • End-to-end operational validation: prescription flow, DSCSA documentation, invoicing, health plan reporting, member experience
Phase 4Month 5

Review and Channel Preparation

  • Performance review with manufacturer teams
  • Reporting formats finalized
  • Commercial team briefed on live channel for use in employer account discussions
Phase 5Month 6

Scale

  • Additional employer and health plan clients onboarded
  • Monthly JIT cadence and consolidated reporting fully operational
Phase 6Ongoing

Growth

  • Manufacturer commercial team references the live DTE channel with employer accounts
  • Additional drug categories activated
Activate Your Channel

The Infrastructure Is Built. Activation Is the Only Remaining Step.

Contact us to discuss your portfolio, your existing distribution model, and the fastest path to a live direct-to-employer deployment.

Schedule a Briefing